vTv Therapeutics Inc. (VTVT) 10-Year Financial Performance & Capital Metrics

VTVT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutvTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Show more

Revenue $1M
EBITDA -$24M +5.2%
Net Income -$18M +8.8%
EPS (Diluted) -3.20 +67.0%
Gross Margin 100%
EBITDA Margin -2368.83%
Operating Margin -2377.58%
Net Margin -1815.34%
ROE -129.1%
ROIC -
Debt/Equity 0.01
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Sales declining 18.1% over 5 years
✗Shares diluted 100.0% in last year
✗Expensive at 15.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-4.12%

5Y-18.12%

3Y-36.68%

TTM-98.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM24.94%

ROCE

10Y Avg-196.63%

5Y Avg-234.26%

3Y Avg-149.08%

Latest-144.49%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	519K	634K	291K	12.43M	2.76M	6.41M	4M	2.02M	0	1.02M
Revenue Growth %	-0.66%	0.22%	-0.54%	41.73%	-0.78%	1.32%	-0.38%	-0.5%	-1%	-
Cost of Goods Sold+	29.58M	45.75M	39.64M	23.04M	15.12M	11.02M	0	0	0	0
COGS % of Revenue	57%	72.16%	136.22%	1.85%	5.47%	1.72%	-	-	-	-
Gross Profit+	-29.07M	-45.11M	-39.35M	-10.6M	-12.36M	-4.6M	4M	2.02M	0	1.02M
Gross Margin %	-56%	-71.16%	-135.22%	-0.85%	-4.47%	-0.72%	1%	1%	-	1%
Gross Profit Growth %	-0.69%	-0.55%	0.13%	0.73%	-0.17%	0.63%	1.87%	-0.5%	-1%	-
Operating Expenses+	38.66M	55.65M	50.97M	32.26M	23.66M	7.25M	25.67M	24.56M	25.5M	25.2M
OpEx % of Revenue	74.49%	87.78%	175.16%	2.59%	8.56%	1.13%	6.41%	12.17%	-	24.78%
Selling, General & Admin	9.08M	9.91M	11.33M	9.22M	8.54M	7.25M	12.34M	12.2M	11.91M	13.65M
SG&A % of Revenue	17.49%	15.62%	38.95%	0.74%	3.09%	1.13%	3.08%	6.05%	-	13.42%
Research & Development	29.58M	45.75M	39.64M	23.04M	15.12M	11.02M	13.32M	12.36M	13.6M	11.55M
R&D % of Revenue	57%	72.16%	136.22%	1.85%	5.47%	1.72%	3.33%	6.12%	-	11.35%
Other Operating Expenses	-2.96M	-22K	-190K	-592K	0	-11.02M	0	0	0	0
Operating Income+	-38.14M	-55.02M	-50.68M	-19.82M	-20.89M	-11.85M	-21.66M	-22.54M	-25.5M	-24.18M
Operating Margin %	-73.49%	-86.78%	-174.16%	-1.59%	-7.56%	-1.85%	-5.41%	-11.17%	-	-23.78%
Operating Income Growth %	-0.32%	-0.44%	0.08%	0.61%	-0.05%	0.43%	-0.83%	-0.04%	-0.13%	0.05%
EBITDA+	-37.64M	-54.76M	-50.48M	-19.61M	-20.85M	-11.76M	-21.57M	-22.45M	-25.41M	-24.09M
EBITDA Margin %	-72.53%	-86.36%	-173.49%	-1.58%	-7.54%	-1.83%	-5.39%	-11.12%	-	-23.69%
EBITDA Growth %	-0.34%	-0.45%	0.08%	0.61%	-0.06%	0.44%	-0.83%	-0.04%	-0.13%	0.05%
D&A (Non-Cash Add-back)	501K	265K	197K	218K	39K	94K	89K	92K	90K	89K
EBIT	-39.33M	-54.95M	-50.76M	-20.36M	-20.01M	-12.11M	-17.6M	-24.86M	-25.95M	-22.61M
Net Interest Income+	-1.74M	-311K	-2.98M	-3.23M	-1.77M	-680K	-11K	337K	459K	1.56M
Interest Income	0	87K	117K	61K	53K	12K	1K	352K	472K	1.56M
Interest Expense	1.74M	398K	3.09M	3.29M	1.83M	692K	12K	15K	13K	0
Other Income/Expense	-2.96M	-333K	-3.17M	-3.82M	-946K	-950K	4.05M	-2.33M	-464K	1.57M
Pretax Income+	-41.11M	-55.35M	-53.85M	-23.64M	-21.84M	-12.8M	-17.62M	-24.87M	-25.97M	-22.61M
Pretax Margin %	-79.2%	-87.31%	-185.04%	-1.9%	-7.9%	-2%	-4.4%	-12.33%	-	-22.23%
Income Tax+	0	0	800K	200K	100K	0	115K	200K	0	100K
Effective Tax Rate %	0.67%	0.3%	0.3%	0.33%	1%	0.66%	0.74%	0.77%	0.78%	0.82%
Net Income+	-27.5M	-16.35M	-16.14M	-7.91M	-21.94M	-8.5M	-12.99M	-19.16M	-20.25M	-18.46M
Net Margin %	-52.98%	-25.79%	-55.48%	-0.64%	-7.94%	-1.33%	-3.24%	-9.5%	-	-18.15%
Net Income Growth %	0.24%	0.41%	0.01%	0.51%	-1.77%	0.61%	-0.53%	-0.48%	-0.06%	0.09%
Net Income (Continuing)	-41.11M	-55.35M	-54.65M	-23.84M	-21.94M	-12.8M	-17.73M	-25.07M	-25.97M	-22.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	161.53M	122.52M	131.44M	62.48M	40.18M	83.89M	24.96M	16.58M	6.13M	2.1M
EPS (Diluted)+	-132.90	-68.52	-66.62	-25.42	-28.97	-7.21	-8.29	-9.98	-9.71	-3.20
EPS Growth %	0.24%	0.48%	0.03%	0.62%	-0.14%	0.75%	-0.15%	-0.2%	0.03%	0.67%
EPS (Basic)	-132.90	-68.52	-66.62	-25.42	-28.97	-7.21	-8.29	-9.98	-9.71	-3.20
Diluted Shares Outstanding	206.91K	238.64K	242.33K	311.23K	757.3K	1.18M	1.57M	1.92M	2.08M	5.77M
Basic Shares Outstanding	206.91K	238.64K	242.33K	311.23K	757.3K	1.18M	1.57M	1.92M	2.08M	5.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	89.19M	52.12M	20.36M	3.47M	2.84M	7.21M	15.62M	27.09M	10.66M	38.11M
Cash & Short-Term Investments	88M	51.51M	11.76M	1.68M	1.78M	5.75M	13.41M	12.13M	9.45M	36.75M
Cash Only	88M	51.51M	11.76M	1.68M	1.78M	5.75M	13.41M	12.13M	9.45M	36.75M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	69K	0	8M	0	5K	158K	57K	12.42M	102K	62K
Days Sales Outstanding	48.53	-	10.03K	-	0.66	8.99	5.19	2.25K	-	22.25
Inventory	0	0	162K	0	0	371K	100K	0	0	0
Days Inventory Outstanding	-	-	1.49	-	-	12.29	-	-	-	-
Other Current Assets	1.11M	612K	442K	666K	0	0	35K	0	0	0
Total Non-Current Assets+	2.35M	2.38M	7.55M	5.09M	6.43M	7.57M	9.85M	6.14M	361K	153K
Property, Plant & Equipment	624K	444K	283K	70K	1M	849K	680K	556K	361K	153K
Fixed Asset Turnover	0.83x	1.43x	1.03x	177.63x	2.75x	7.55x	5.89x	3.63x	-	6.65x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	49K	0	2.48M	2.48M	2.48M	6.72M	9.17M	5.59M	0	0
Other Non-Current Assets	1.67M	1.93M	4.79M	2.54M	2.94M	0	0	0	0	0
Total Assets+	91.53M	54.49M	27.92M	8.56M	9.27M	14.79M	25.47M	33.24M	11.02M	38.27M
Asset Turnover	0.01x	0.01x	0.01x	1.45x	0.30x	0.43x	0.16x	0.06x	-	0.03x
Asset Growth %	6.07%	-0.4%	-0.49%	-0.69%	0.08%	0.6%	0.72%	0.3%	-0.67%	2.47%
Total Current Liabilities+	7.73M	11.43M	26.93M	18.84M	13.38M	6.39M	8.5M	7.71M	10.62M	5.2M
Accounts Payable	4.14M	3.06M	2.27M	2.9M	2.23M	1.93M	1.88M	2.46M	4.08M	939K
Days Payables Outstanding	51.1	24.41	20.89	45.94	53.88	63.79	-	-	-	-
Short-Term Debt	0	0	4.27M	9.38M	6.17M	84K	256K	224K	191K	0
Deferred Revenue (Current)	219K	21K	1000K	1000K	31K	31K	35K	17K	17K	0
Other Current Liabilities	2.33M	6.88M	0	0	1.56M	1.59M	3.2M	788K	4.7M	1.51M
Current Ratio	11.54x	4.56x	0.76x	0.18x	0.21x	1.13x	1.84x	3.52x	1.00x	7.34x
Quick Ratio	11.54x	4.56x	0.75x	0.18x	0.21x	1.07x	1.83x	3.52x	1.00x	7.34x
Cash Conversion Cycle	-	-	10.01K	-	-	-42.5	-	-	-	-
Total Non-Current Liabilities+	161.78M	134.01M	152.03M	72.58M	4.72M	4.61M	1.75M	19.69M	18.95M	18.77M
Long-Term Debt	0	11.06M	15.32M	6.33M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	831K	676K	492K	338K	169K	0
Deferred Tax Liabilities	0	0	131.93M	64.92M	0	0	0	0	0	0
Other Non-Current Liabilities	245K	433K	782K	2.7M	2.86M	2.92M	1.26M	684K	110K	100K
Total Liabilities	169.5M	145.44M	178.96M	91.41M	18.11M	11M	10.25M	27.4M	29.57M	23.96M
Total Debt+	0	11.06M	19.59M	15.71M	7.11M	915K	932K	716K	529K	169K
Net Debt	-88M	-40.45M	7.83M	14.03M	5.34M	-4.83M	-12.48M	-11.41M	-8.92M	-36.58M
Debt / Equity	-	0.35x	-	-	-	0.24x	0.06x	0.12x	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-21.98x	-138.24x	-16.39x	-6.03x	-11.44x	-17.13x	-1805.17x	-1502.67x	-1961.69x	-
Total Equity+	83.56M	31.57M	-19.61M	-20.37M	-8.84M	3.79M	15.22M	5.84M	-18.55M	14.3M
Equity Growth %	1.17%	-0.62%	-1.62%	-0.04%	0.57%	1.43%	3.01%	-0.62%	-4.18%	1.77%
Book Value per Share	403.85	132.29	-80.91	-65.45	-11.67	3.22	9.72	3.04	-8.90	2.48
Total Shareholders' Equity	-77.97M	-90.94M	-151.05M	-82.85M	-49.02M	-80.1M	-9.74M	-10.74M	-24.68M	12.2M
Common Stock	329K	329K	329K	435K	641K	773K	901K	27K	27K	32K
Retained Earnings	-195.99M	-215.49M	-279.06M	-233.88M	-233.52M	-290.04M	-248.83M	-265.52M	-281.04M	-299.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-11.09M	-10.45M	-9.12M	-8.43M	0	0	0	0	0	0
Minority Interest	161.53M	122.52M	131.44M	62.48M	40.18M	83.89M	24.96M	16.58M	6.13M	2.1M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-36.95M	-48.21M	-44.56M	-26.86M	-23.02M	-18M	-19.31M	-15.25M	-19.08M	-25.31M
Operating CF Margin %	-71.19%	-76.04%	-153.13%	-2.16%	-8.33%	-2.81%	-4.82%	-7.56%	-	-24.88%
Operating CF Growth %	-0.2%	-0.3%	0.08%	0.4%	0.14%	0.22%	-0.07%	0.21%	-0.25%	-0.33%
Net Income	-41.11M	-55.35M	-54.65M	-23.84M	-21.94M	-12.8M	-17.73M	-19.16M	-20.25M	-22.7M
Depreciation & Amortization	501K	265K	197K	218K	39K	94K	89K	92K	90K	89K
Stock-Based Compensation	859K	2.64M	3.65M	2.68M	1.52M	1.01M	2.36M	0	1.58M	2.76M
Deferred Taxes	38K	-2K	179K	626K	-1.11M	-3.98M	0	0	0	0
Other Non-Cash Items	722K	154K	1.03M	1.01M	532K	380K	-4.06M	-1.56M	-4.89M	-10K
Working Capital Changes	2.04M	4.09M	5.04M	-7.54M	-2.05M	-2.71M	35K	5.38M	4.39M	-5.44M
Change in Receivables	-69K	69K	-8M	8M	-5K	-153K	101K	-116K	71K	40K
Change in Inventory	547K	-359K	194K	0	618K	-1.98M	-889K	0	0	0
Change in Payables	2.93M	4.79M	2.45M	-6.2M	-618K	-997K	1.83M	-856K	2.93M	0
Cash from Investing+	-79K	-83K	-25K	7K	242K	0	0	-21K	4.4M	0
Capital Expenditures	-104K	-87K	-57K	-5K	-70K	0	0	-21K	0	0
CapEx % of Revenue	0.2%	0.14%	0.2%	0%	0.03%	-	-	0.01%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	25K	4K	32K	12K	0	0	0	0	-4.4M	0
Cash from Financing+	123.64M	11.79M	7.5M	16.61M	22.87M	19.47M	26.98M	13.98M	12M	52.61M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-89K	-673K	0	0	0	0	47K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.05M	-48.3M	-44.62M	-26.86M	-23.09M	-18M	-19.31M	-15.27M	-19.08M	-25.31M
FCF Margin %	-71.39%	-76.18%	-153.32%	-2.16%	-8.35%	-2.81%	-4.82%	-7.57%	-	-24.88%
FCF Growth %	-0.2%	-0.3%	0.08%	0.4%	0.14%	0.22%	-0.07%	0.21%	-0.25%	-0.33%
FCF per Share	-179.06	-202.38	-184.12	-86.31	-30.49	-15.27	-12.33	-7.95	-9.15	-4.39
FCF Conversion (FCF/Net Income)	1.34x	2.95x	2.76x	3.39x	1.05x	2.12x	1.49x	0.80x	0.94x	1.37x
Interest Paid	0	0	0	2.28M	1.29M	0	11K	0	0	2K
Taxes Paid	0	0	0	1M	100K	0	115K	0	0	100K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.91%	-28.41%	-269.9%	-	-	-224.07%	-136.6%	-181.99%	-	-129.1%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-1911.35%	-	-	-
Gross Margin	-5600.19%	-7115.77%	-13521.99%	-85.26%	-447%	-71.73%	100%	100%	-	100%
Net Margin	-5298.27%	-2579.18%	-5547.77%	-63.62%	-793.7%	-132.51%	-324.27%	-949.65%	-	-1815.34%
Debt / Equity	-	0.35x	-	-	-	0.24x	0.06x	0.12x	-	0.01x
Interest Coverage	-21.98x	-138.24x	-16.39x	-6.03x	-11.44x	-17.13x	-1805.17x	-1502.67x	-1961.69x	-
FCF Conversion	1.34x	2.95x	2.76x	3.39x	1.05x	2.12x	1.49x	0.80x	0.94x	1.37x
Revenue Growth	-66.49%	22.16%	-54.1%	4172.85%	-77.77%	132.05%	-37.56%	-49.61%	-100%	-

Revenue by Segment

	2024
Reportable	1M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

vTv Therapeutics Inc. (VTVT) reported $0.0M in revenue for fiscal year 2024. This represents a 98% decrease from $1.0M in 2013.

vTv Therapeutics Inc. (VTVT) grew revenue by 0.0% over the past year. Growth has been modest.

vTv Therapeutics Inc. (VTVT) reported a net loss of $23.5M for fiscal year 2024.

Dividend & Returns

vTv Therapeutics Inc. (VTVT) has a return on equity (ROE) of -129.1%. Negative ROE indicates the company is unprofitable.

vTv Therapeutics Inc. (VTVT) had negative free cash flow of $20.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

vTv Therapeutics Inc. (VTVT) 10-Year Financial Performance & Capital Metrics

VTVT • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $1M
EBITDA -$24M +5.2%
Net Income -$18M +8.8%
EPS (Diluted) -3.20 +67.0%
Gross Margin 100%
EBITDA Margin -2368.83%
Operating Margin -2377.58%
Net Margin -1815.34%
ROE -129.1%
ROIC -
Debt/Equity 0.01
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Negative free cash flow
✗Sales declining 18.1% over 5 years
✗Shares diluted 100.0% in last year
✗Expensive at 15.1x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-4.12%

5Y-18.12%

3Y-36.68%

TTM-98.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM24.94%

ROCE

10Y Avg-196.63%

5Y Avg-234.26%

3Y Avg-149.08%

Latest-144.49%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.73B	5.64	58.02	43.5%	9.32%		1.89%
CORTCorcept Therapeutics Incorporated	3.82B	36.35	29.55	39.94%	14.19%	16.65%	5.12%	0.01
GUTSFractyl Health, Inc. Common Stock	308.28M	2.01	-1.24	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	436.08M	1.20	-1.90	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	229.96M	2.48	-2.53			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	164.38M	1.93	-2.88	-100%		-282.97%		4.17
ALTAltimmune, Inc.	418.41M	4.01	-2.99	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	741.84M	20.69	-3.12		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	519K	634K	291K	12.43M	2.76M	6.41M	4M	2.02M	0	1.02M
Revenue Growth %	-0.66%	0.22%	-0.54%	41.73%	-0.78%	1.32%	-0.38%	-0.5%	-1%	-
Cost of Goods Sold+	29.58M	45.75M	39.64M	23.04M	15.12M	11.02M	0	0	0	0
COGS % of Revenue	57%	72.16%	136.22%	1.85%	5.47%	1.72%	-	-	-	-
Gross Profit+	-29.07M	-45.11M	-39.35M	-10.6M	-12.36M	-4.6M	4M	2.02M	0	1.02M
Gross Margin %	-56%	-71.16%	-135.22%	-0.85%	-4.47%	-0.72%	1%	1%	-	1%
Gross Profit Growth %	-0.69%	-0.55%	0.13%	0.73%	-0.17%	0.63%	1.87%	-0.5%	-1%	-
Operating Expenses+	38.66M	55.65M	50.97M	32.26M	23.66M	7.25M	25.67M	24.56M	25.5M	25.2M
OpEx % of Revenue	74.49%	87.78%	175.16%	2.59%	8.56%	1.13%	6.41%	12.17%	-	24.78%
Selling, General & Admin	9.08M	9.91M	11.33M	9.22M	8.54M	7.25M	12.34M	12.2M	11.91M	13.65M
SG&A % of Revenue	17.49%	15.62%	38.95%	0.74%	3.09%	1.13%	3.08%	6.05%	-	13.42%
Research & Development	29.58M	45.75M	39.64M	23.04M	15.12M	11.02M	13.32M	12.36M	13.6M	11.55M
R&D % of Revenue	57%	72.16%	136.22%	1.85%	5.47%	1.72%	3.33%	6.12%	-	11.35%
Other Operating Expenses	-2.96M	-22K	-190K	-592K	0	-11.02M	0	0	0	0
Operating Income+	-38.14M	-55.02M	-50.68M	-19.82M	-20.89M	-11.85M	-21.66M	-22.54M	-25.5M	-24.18M
Operating Margin %	-73.49%	-86.78%	-174.16%	-1.59%	-7.56%	-1.85%	-5.41%	-11.17%	-	-23.78%
Operating Income Growth %	-0.32%	-0.44%	0.08%	0.61%	-0.05%	0.43%	-0.83%	-0.04%	-0.13%	0.05%
EBITDA+	-37.64M	-54.76M	-50.48M	-19.61M	-20.85M	-11.76M	-21.57M	-22.45M	-25.41M	-24.09M
EBITDA Margin %	-72.53%	-86.36%	-173.49%	-1.58%	-7.54%	-1.83%	-5.39%	-11.12%	-	-23.69%
EBITDA Growth %	-0.34%	-0.45%	0.08%	0.61%	-0.06%	0.44%	-0.83%	-0.04%	-0.13%	0.05%
D&A (Non-Cash Add-back)	501K	265K	197K	218K	39K	94K	89K	92K	90K	89K
EBIT	-39.33M	-54.95M	-50.76M	-20.36M	-20.01M	-12.11M	-17.6M	-24.86M	-25.95M	-22.61M
Net Interest Income+	-1.74M	-311K	-2.98M	-3.23M	-1.77M	-680K	-11K	337K	459K	1.56M
Interest Income	0	87K	117K	61K	53K	12K	1K	352K	472K	1.56M
Interest Expense	1.74M	398K	3.09M	3.29M	1.83M	692K	12K	15K	13K	0
Other Income/Expense	-2.96M	-333K	-3.17M	-3.82M	-946K	-950K	4.05M	-2.33M	-464K	1.57M
Pretax Income+	-41.11M	-55.35M	-53.85M	-23.64M	-21.84M	-12.8M	-17.62M	-24.87M	-25.97M	-22.61M
Pretax Margin %	-79.2%	-87.31%	-185.04%	-1.9%	-7.9%	-2%	-4.4%	-12.33%	-	-22.23%
Income Tax+	0	0	800K	200K	100K	0	115K	200K	0	100K
Effective Tax Rate %	0.67%	0.3%	0.3%	0.33%	1%	0.66%	0.74%	0.77%	0.78%	0.82%
Net Income+	-27.5M	-16.35M	-16.14M	-7.91M	-21.94M	-8.5M	-12.99M	-19.16M	-20.25M	-18.46M
Net Margin %	-52.98%	-25.79%	-55.48%	-0.64%	-7.94%	-1.33%	-3.24%	-9.5%	-	-18.15%
Net Income Growth %	0.24%	0.41%	0.01%	0.51%	-1.77%	0.61%	-0.53%	-0.48%	-0.06%	0.09%
Net Income (Continuing)	-41.11M	-55.35M	-54.65M	-23.84M	-21.94M	-12.8M	-17.73M	-25.07M	-25.97M	-22.7M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	161.53M	122.52M	131.44M	62.48M	40.18M	83.89M	24.96M	16.58M	6.13M	2.1M
EPS (Diluted)+	-132.90	-68.52	-66.62	-25.42	-28.97	-7.21	-8.29	-9.98	-9.71	-3.20
EPS Growth %	0.24%	0.48%	0.03%	0.62%	-0.14%	0.75%	-0.15%	-0.2%	0.03%	0.67%
EPS (Basic)	-132.90	-68.52	-66.62	-25.42	-28.97	-7.21	-8.29	-9.98	-9.71	-3.20
Diluted Shares Outstanding	206.91K	238.64K	242.33K	311.23K	757.3K	1.18M	1.57M	1.92M	2.08M	5.77M
Basic Shares Outstanding	206.91K	238.64K	242.33K	311.23K	757.3K	1.18M	1.57M	1.92M	2.08M	5.77M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	89.19M	52.12M	20.36M	3.47M	2.84M	7.21M	15.62M	27.09M	10.66M	38.11M
Cash & Short-Term Investments	88M	51.51M	11.76M	1.68M	1.78M	5.75M	13.41M	12.13M	9.45M	36.75M
Cash Only	88M	51.51M	11.76M	1.68M	1.78M	5.75M	13.41M	12.13M	9.45M	36.75M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	69K	0	8M	0	5K	158K	57K	12.42M	102K	62K
Days Sales Outstanding	48.53	-	10.03K	-	0.66	8.99	5.19	2.25K	-	22.25
Inventory	0	0	162K	0	0	371K	100K	0	0	0
Days Inventory Outstanding	-	-	1.49	-	-	12.29	-	-	-	-
Other Current Assets	1.11M	612K	442K	666K	0	0	35K	0	0	0
Total Non-Current Assets+	2.35M	2.38M	7.55M	5.09M	6.43M	7.57M	9.85M	6.14M	361K	153K
Property, Plant & Equipment	624K	444K	283K	70K	1M	849K	680K	556K	361K	153K
Fixed Asset Turnover	0.83x	1.43x	1.03x	177.63x	2.75x	7.55x	5.89x	3.63x	-	6.65x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	49K	0	2.48M	2.48M	2.48M	6.72M	9.17M	5.59M	0	0
Other Non-Current Assets	1.67M	1.93M	4.79M	2.54M	2.94M	0	0	0	0	0
Total Assets+	91.53M	54.49M	27.92M	8.56M	9.27M	14.79M	25.47M	33.24M	11.02M	38.27M
Asset Turnover	0.01x	0.01x	0.01x	1.45x	0.30x	0.43x	0.16x	0.06x	-	0.03x
Asset Growth %	6.07%	-0.4%	-0.49%	-0.69%	0.08%	0.6%	0.72%	0.3%	-0.67%	2.47%
Total Current Liabilities+	7.73M	11.43M	26.93M	18.84M	13.38M	6.39M	8.5M	7.71M	10.62M	5.2M
Accounts Payable	4.14M	3.06M	2.27M	2.9M	2.23M	1.93M	1.88M	2.46M	4.08M	939K
Days Payables Outstanding	51.1	24.41	20.89	45.94	53.88	63.79	-	-	-	-
Short-Term Debt	0	0	4.27M	9.38M	6.17M	84K	256K	224K	191K	0
Deferred Revenue (Current)	219K	21K	1000K	1000K	31K	31K	35K	17K	17K	0
Other Current Liabilities	2.33M	6.88M	0	0	1.56M	1.59M	3.2M	788K	4.7M	1.51M
Current Ratio	11.54x	4.56x	0.76x	0.18x	0.21x	1.13x	1.84x	3.52x	1.00x	7.34x
Quick Ratio	11.54x	4.56x	0.75x	0.18x	0.21x	1.07x	1.83x	3.52x	1.00x	7.34x
Cash Conversion Cycle	-	-	10.01K	-	-	-42.5	-	-	-	-
Total Non-Current Liabilities+	161.78M	134.01M	152.03M	72.58M	4.72M	4.61M	1.75M	19.69M	18.95M	18.77M
Long-Term Debt	0	11.06M	15.32M	6.33M	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	831K	676K	492K	338K	169K	0
Deferred Tax Liabilities	0	0	131.93M	64.92M	0	0	0	0	0	0
Other Non-Current Liabilities	245K	433K	782K	2.7M	2.86M	2.92M	1.26M	684K	110K	100K
Total Liabilities	169.5M	145.44M	178.96M	91.41M	18.11M	11M	10.25M	27.4M	29.57M	23.96M
Total Debt+	0	11.06M	19.59M	15.71M	7.11M	915K	932K	716K	529K	169K
Net Debt	-88M	-40.45M	7.83M	14.03M	5.34M	-4.83M	-12.48M	-11.41M	-8.92M	-36.58M
Debt / Equity	-	0.35x	-	-	-	0.24x	0.06x	0.12x	-	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-21.98x	-138.24x	-16.39x	-6.03x	-11.44x	-17.13x	-1805.17x	-1502.67x	-1961.69x	-
Total Equity+	83.56M	31.57M	-19.61M	-20.37M	-8.84M	3.79M	15.22M	5.84M	-18.55M	14.3M
Equity Growth %	1.17%	-0.62%	-1.62%	-0.04%	0.57%	1.43%	3.01%	-0.62%	-4.18%	1.77%
Book Value per Share	403.85	132.29	-80.91	-65.45	-11.67	3.22	9.72	3.04	-8.90	2.48
Total Shareholders' Equity	-77.97M	-90.94M	-151.05M	-82.85M	-49.02M	-80.1M	-9.74M	-10.74M	-24.68M	12.2M
Common Stock	329K	329K	329K	435K	641K	773K	901K	27K	27K	32K
Retained Earnings	-195.99M	-215.49M	-279.06M	-233.88M	-233.52M	-290.04M	-248.83M	-265.52M	-281.04M	-299.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-11.09M	-10.45M	-9.12M	-8.43M	0	0	0	0	0	0
Minority Interest	161.53M	122.52M	131.44M	62.48M	40.18M	83.89M	24.96M	16.58M	6.13M	2.1M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-36.95M	-48.21M	-44.56M	-26.86M	-23.02M	-18M	-19.31M	-15.25M	-19.08M	-25.31M
Operating CF Margin %	-71.19%	-76.04%	-153.13%	-2.16%	-8.33%	-2.81%	-4.82%	-7.56%	-	-24.88%
Operating CF Growth %	-0.2%	-0.3%	0.08%	0.4%	0.14%	0.22%	-0.07%	0.21%	-0.25%	-0.33%
Net Income	-41.11M	-55.35M	-54.65M	-23.84M	-21.94M	-12.8M	-17.73M	-19.16M	-20.25M	-22.7M
Depreciation & Amortization	501K	265K	197K	218K	39K	94K	89K	92K	90K	89K
Stock-Based Compensation	859K	2.64M	3.65M	2.68M	1.52M	1.01M	2.36M	0	1.58M	2.76M
Deferred Taxes	38K	-2K	179K	626K	-1.11M	-3.98M	0	0	0	0
Other Non-Cash Items	722K	154K	1.03M	1.01M	532K	380K	-4.06M	-1.56M	-4.89M	-10K
Working Capital Changes	2.04M	4.09M	5.04M	-7.54M	-2.05M	-2.71M	35K	5.38M	4.39M	-5.44M
Change in Receivables	-69K	69K	-8M	8M	-5K	-153K	101K	-116K	71K	40K
Change in Inventory	547K	-359K	194K	0	618K	-1.98M	-889K	0	0	0
Change in Payables	2.93M	4.79M	2.45M	-6.2M	-618K	-997K	1.83M	-856K	2.93M	0
Cash from Investing+	-79K	-83K	-25K	7K	242K	0	0	-21K	4.4M	0
Capital Expenditures	-104K	-87K	-57K	-5K	-70K	0	0	-21K	0	0
CapEx % of Revenue	0.2%	0.14%	0.2%	0%	0.03%	-	-	0.01%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	25K	4K	32K	12K	0	0	0	0	-4.4M	0
Cash from Financing+	123.64M	11.79M	7.5M	16.61M	22.87M	19.47M	26.98M	13.98M	12M	52.61M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-89K	-673K	0	0	0	0	47K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.05M	-48.3M	-44.62M	-26.86M	-23.09M	-18M	-19.31M	-15.27M	-19.08M	-25.31M
FCF Margin %	-71.39%	-76.18%	-153.32%	-2.16%	-8.35%	-2.81%	-4.82%	-7.57%	-	-24.88%
FCF Growth %	-0.2%	-0.3%	0.08%	0.4%	0.14%	0.22%	-0.07%	0.21%	-0.25%	-0.33%
FCF per Share	-179.06	-202.38	-184.12	-86.31	-30.49	-15.27	-12.33	-7.95	-9.15	-4.39
FCF Conversion (FCF/Net Income)	1.34x	2.95x	2.76x	3.39x	1.05x	2.12x	1.49x	0.80x	0.94x	1.37x
Interest Paid	0	0	0	2.28M	1.29M	0	11K	0	0	2K
Taxes Paid	0	0	0	1M	100K	0	115K	0	0	100K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-32.91%	-28.41%	-269.9%	-	-	-224.07%	-136.6%	-181.99%	-	-129.1%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-1911.35%	-	-	-
Gross Margin	-5600.19%	-7115.77%	-13521.99%	-85.26%	-447%	-71.73%	100%	100%	-	100%
Net Margin	-5298.27%	-2579.18%	-5547.77%	-63.62%	-793.7%	-132.51%	-324.27%	-949.65%	-	-1815.34%
Debt / Equity	-	0.35x	-	-	-	0.24x	0.06x	0.12x	-	0.01x
Interest Coverage	-21.98x	-138.24x	-16.39x	-6.03x	-11.44x	-17.13x	-1805.17x	-1502.67x	-1961.69x	-
FCF Conversion	1.34x	2.95x	2.76x	3.39x	1.05x	2.12x	1.49x	0.80x	0.94x	1.37x
Revenue Growth	-66.49%	22.16%	-54.1%	4172.85%	-77.77%	132.05%	-37.56%	-49.61%	-100%	-

Revenue by Segment

	2024
Reportable	1M
Reportable Growth	-

Frequently Asked Questions

Growth & Financials

vTv Therapeutics Inc. (VTVT) reported $0.0M in revenue for fiscal year 2024. This represents a 98% decrease from $1.0M in 2013.

vTv Therapeutics Inc. (VTVT) grew revenue by 0.0% over the past year. Growth has been modest.

vTv Therapeutics Inc. (VTVT) reported a net loss of $23.5M for fiscal year 2024.

Dividend & Returns

vTv Therapeutics Inc. (VTVT) has a return on equity (ROE) of -129.1%. Negative ROE indicates the company is unprofitable.

vTv Therapeutics Inc. (VTVT) had negative free cash flow of $20.8M in fiscal year 2024, likely due to heavy capital investments.